David Marchant, PhD
David Marchant is a Professor in the Department of Medical Microbiology and Immunology at the University of Alberta. Dr Marchant is also a Canada Research Chair in Viral Pathogenesis and the founder and CSO of Antibiddies Technologies Inc., which is developing a drug called RespVirex. The drug is being formulated into a preventative antiviral nasal spray that can be given to infants and adults with ease. The drugs being developed by his company are derived from his research program at the University of Alberta that studies respiratory viruses like SARS-CoV-2 and Respiratory Syncytial Virus.
Publications
- Mapping Respiratory Syncytial Virus Fusion Protein Interactions with the Receptor IGF1R and the Impact of Alanine-scanning Mutagenesis on Viral Infection
- Structure-Based Discovery of Allosteric Inhibitors Targeting a New Druggable Site in the Respiratory Syncytial Virus Polymerase
- A Single Amino Acid Mutation Alters the Neutralization Epitopes in the Respiratory Syncytial Virus Fusion Glycoprotein